Contract facts
FederalEVALUATION OF THE INTRAVENOUS IMMUNE GLOBULIN DEMONSTRATION: THE PURPOSE OF THIS REQUIREMENT IS TO SECURE A QUALIFIED VENDOR TO DESIGN AND CARRY OUT AN INDEPENDENT EVALUATION THAT INFORMS THE INTERMEDIATE AND FINAL REPORT TO CONGRESS (RTC). THIS EFFO is a federal award for Ofc Of Acquisition And Grants Mgmt held by Dobson, Davanzo & Associates, LLC. Estimated value $25.4M ($26.1M obligated). Current period of performance ends Aug 30, 2025 (potential Sep 26, 2025). Last award drew 1 bidder. Place of performance: WINDSOR MILL MD.
EVALUATION OF THE INTRAVENOUS IMMUNE GLOBULIN DEMONSTRATION: THE PURPOSE OF THIS REQUIREMENT IS TO SECURE A QUALIFIED VENDOR TO DESIGN AND CARRY OUT AN INDEPENDENT EVALUATION THAT INFORMS THE INTERMEDIATE AND FINAL REPORT TO CONGRESS (RTC). THIS EFFO
Recompete timing
PublicCurrent PoP ended Aug 30, 2025 (356 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordDobson, Davanzo & Associates, LLC — $12.8M obligated across 16 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75FCMC22F0007?
75FCMC22F0007 (Evaluation of the intravenous IMMUNE globulin) is a Ofc Of Acquisition And Grants Mgmt award with a potential value of $25.4M, currently held by Dobson, Davanzo & Associates, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 75FCMC-22-F-0007?
75FCMC-22-F-0007 is the dashed form of PIID 75FCMC22F0007 (Evaluation of the intravenous IMMUNE globulin), held by Dobson, Davanzo & Associates, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 75FCMC22F0007?
Ofc Of Acquisition And Grants Mgmt awarded 75FCMC22F0007 to Dobson, Davanzo & Associates, LLC (potential $25.4M).
Who is the incumbent on 75FCMC22F0007?
Dobson, Davanzo & Associates, LLC is the incumbent with $12.8M across 16 related awards in SCOUT’s public footprint. The current period of performance ends Aug 30, 2025.
When does Dobson, Davanzo & Associates, LLC’s 75FCMC22F0007 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 30, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.